https://femasys.com/news/how-diversity-and-motherhood-fortified-me-as-a-womens-health-ceo/ 2022-08-01T09:00:00+00:00 https://femasys.com/news/femasys-innovating-womens-reproductive-health-with-minimally-invasive-in-office-technologies/ 2022-08-30T09:00:00+00:00 https://femasys.com/news/tech-companies-working-on-contraception-face-a-new-landscape-after-roe/ 2022-09-08T09:00:00+00:00 https://femasys.com/news/femasys-inc-announces-the-commercial-availability-of-femcerv-for-cervical-cancer-screening-and-expands-management-team/ 2022-09-29T09:00:00+00:00 https://femasys.com/news/femasys-inc-announces-enrollment-completion-for-stage-2-study-of-fembloc-for-permanent-birth-control/ 2022-10-06T09:00:00+00:00 https://femasys.com/news/femasys-inc-announces-the-appointment-of-christine-thomas-as-senior-vice-president-of-regulatory-and-clinical-affairs/ 2022-10-12T09:00:00+00:00 https://femasys.com/news/femasys-inc-provides-strategic-update-on-its-femaseed-pivotal-trial-design-to-expedite-cli/ 2022-10-20T09:00:00+00:00 https://femasys.com/news/femasys-targets-male-infertility-with-updated-trial-design/ 2022-11-03T09:00:00+00:00 https://femasys.com/news/femasys-announces-commercial-availability-of-femcath/ 2022-11-15T09:00:00+00:00 https://femasys.com/news/us-biomedical-company-launches-intrauterine-device-for-tubal-evaluation/ 2023-01-09T09:00:00+00:00 https://femasys.com/news/the-post-roe-fertility-journey/ 2023-02-22T09:00:00+00:00 https://femasys.com/news/femasys-announces-financial-results-for-year-ended-december-31-2022-and-provides-corporate/ 2023-03-30T09:00:00+00:00 https://femasys.com/news/femcerv-well-designed-technology-that-can-minimize-patient-discomfort/ 2023-04-13T09:00:00+00:00 https://femasys.com/news/femasys-initiates-enrollment-in-pivotal-trial-of-permanent-birth-control-candidate-fembloc/ 2023-08-03T09:00:00+00:00 https://femasys.com/news/femasys-expands-fembloc-pivotal-trial-enrollment-securing-first-academic-site/ 2023-09-27T09:00:00+00:00 https://femasys.com/news/femasys-inc-secures-additional-financing-with-strategic-investment-from-investors-led-by-pharmacyte-biotech/ 2023-11-15T09:00:00+00:00 https://femasys.com/news/femasys-inc-completes-enrollment-of-femaseed-pivotal-trial-in-support-of-commercial-launch/ 2023-11-28T09:00:00+00:00 https://femasys.com/news/femasys-inc-announces-the-appointment-of-james-liu-m-d-as-chief-medical-officer/ 2023-11-30T09:00:00+00:00 https://femasys.com/news/femasys-inc-begins-fembloc-pivotal-trial-enrollment-at-stanford-medicine/ 2023-12-15T09:00:00+00:00 https://femasys.com/news/femasys-inc-begins-fembloc-pivotal-trial-enrollment-at-university-of-utah-an-internationally-recognized-center-in-obstetrics-and-gynecology/ 2024-01-23T09:00:00+00:00 https://femasys.com/news/femasys-inc-begins-fembloc-pivotal-trial-enrollment-at-uc-davis-medical-center-a-hub-for-innovation-and-groundbreaking-research-in-health-care-for-women/ 2024-01-26T09:00:00+00:00 https://femasys.com/news/femasys-inc-advances-commercial-readiness-with-appointment-of-richard-spector-to-new-position-of-chief-commercial-officer/ 2024-02-06T09:00:00+00:00 https://femasys.com/news/femasys-femaseed-fda-clearance-brings-timely-access-to-a-first-line-infertility-treatment-option-as-an-alternative-to-ivf/ 2024-02-28T09:00:00+00:00 https://femasys.com/news/femasys-completes-first-in-office-commercial-procedure-with-fda-cleared-femaseed/ 2024-03-06T09:00:00+00:00 https://femasys.com/news/femasys-announces-positive-topline-data-from-pivotal-trial-for-fda-cleared-femaseed/ 2024-03-20T09:00:00+00:00 https://femasys.com/news/femasys-discloses-positive-data-from-femaseed-trial/ 2024-03-20T09:00:00+00:00 https://femasys.com/news/femaseed-shows-positive-results-for-infertility-treatment/ 2024-03-20T10:00:00+00:00 https://femasys.com/news/femaseed-a-breakthrough-solution-proving-promise-in-overcoming-infertility-challenges/ 2024-03-20T11:00:00+00:00 https://femasys.com/news/femasys-is-committed-to-providing-women-with-revolutionary-healthcare-products-ceo/ 2024-04-04T09:00:00+00:00 https://femasys.com/news/femasys-ceo-and-founder-kathy-lee-sepsick-meets-with-the-white-houses-gender-policy-council/ 2024-05-16T09:00:00+00:00 https://femasys.com/news/femasys-ceo-and-founder-kathy-lee-sepsick-meets-with-the-white-houses-office-of-science-and-technology-policy-to-discuss-the-cancer-moonshot-initiative/ 2024-05-17T09:00:00+00:00 https://femasys.com/news/femasys-founder-kathy-lee-sepsick-on-entrepreneurship-and-the-need-for-innovation-in-women/ 2024-06-04T09:00:00+00:00 https://femasys.com/news/health-tech-kathy-lee-sepsick-of-femasys-on-how-their-technology-can-make-an-important-imp/ 2024-06-12T09:00:00+00:00 https://femasys.com/news/femasys-at-inflection-point-and-undervalued-ceo-says/ 2024-06-17T09:00:00+00:00 https://femasys.com/news/femasys-receives-ce-mark-approval-for-four-of-its-womens-health-products-clearing-the-path-for-the-company-to-begin-commercialization-efforts-in-europe/ 2024-06-20T09:00:00+00:00 https://femasys.com/news/womens-healthcare-will-changing-laws-inhibit-latest-innovations-in-fertility-and-birth-control-treatments/ 2024-07-31T09:00:00+00:00 https://femasys.com/news/providing-safe-and-accessible-options-for-women-s-reproductive-care/ 2024-08-19T09:00:00+00:00 https://femasys.com/news/femasys-secures-ce-mark-certification-for-femvue-mini-solution/ 2024-08-30T09:00:00+00:00 https://femasys.com/news/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-an-innovative-diagnostic-solution-for-fallopian-tube-check/ 2024-09-09T09:00:00+00:00 https://femasys.com/news/femasys-announces-partnership-with-boston-ivf-to-offer-femaseed/ 2024-10-30T09:00:00+00:00 https://femasys.com/news/femasys-partners-with-boston-ivf-to-expand-access-to-novel-fertility-treatment/ 2024-11-05T09:00:00+00:00 https://femasys.com/news/innovation-in-womens-reproductive-health-is-more-important-than-ever/ 2024-11-20T09:00:00+00:00 https://femasys.com/news/femasys-announces-peer-reviewed-publication-of-positive-data-from-prospective-multicenter-pivotal-trial-of-femaseed-infertility-treatment/ 2024-11-26T09:00:00+00:00 https://femasys.com/news/femasys-announces-partnership-with-hrc-fertility-esteemed-conglomerate-provider-of-fertility-services-in-western-u-s-to-offer-femaseed/ 2024-12-03T09:00:00+00:00 https://femasys.com/news/femasys-announces-notice-of-allowance-for-new-u-s-patent-application-covering-use-of-femaseed-for-female-infertility-treatment/ 2025-01-16T09:00:00+00:00 https://femasys.com/news/femasys-announces-notices-of-intention-to-grant-for-two-new-european-patent-applications-covering-use-of-fembloc-permanent-birth-control/ 2025-01-30T10:00:00+00:00 https://femasys.com/news/femasys-announces-israeli-regulatory-approvals-for-femaseed-and-two-diagnostic-devices/ 2025-02-04T09:00:00+00:00 https://femasys.com/news/femasys-offers-a-fresh-take-on-womens-reproductive-healthcare/ 2025-03-04T09:00:00+00:00 https://femasys.com/news/femasys-announces-financial-results-for-year-ended-december-31-2024-and-provides-corporate/ 2025-03-27T09:00:00+00:00 https://femasys.com/news/femasys-announces-historic-milestone-with-european-approval-of-fembloc/ 2025-06-25T09:00:00+00:00 https://femasys.com/news/transforming-womens-health-the-power-of-femtech-and-minimally-invasive-solutions/ 2025-07-15T09:00:00+00:00 https://femasys.com/news/suwanee-company-raising-millions-following-approval-of-birth-control-product/ 2025-08-22T09:00:00+00:00 https://femasys.com/news/femasys-roadmap-for-fembloc-in-europe/ 2025-10-01T09:00:00+00:00 https://femasys.com/news/metro-atlanta-woman-invents-a-nonsurgical-form-of-permanent-birth-control/ 2025-10-29T09:00:00+00:00 https://femasys.com/news/femasys-secures-fda-approval-to-advance-final-fembloc-trial-phase-and-12-million-financing-with-potential-to-reach-58-million/ 2025-11-03T09:00:00+00:00 https://femasys.com/news/how-femasys-is-using-innovation-to-rethink-permanent-birth-control/ 2025-11-05T09:00:00+00:00 https://femasys.com/news/femasys-advances-global-growth-with-second-partner-order-for-fembloc-in-europe/ 2025-11-10T09:00:00+00:00 https://femasys.com/news/femasys-announces-third-quarter-financial-results-for-2025/ 2025-11-14T09:00:00+00:00 https://femasys.com/news/femasys-secures-u-s-fda-clearance-for-next-generation-femvue-diagnostic-device/ 2025-12-18T09:00:00+00:00 https://femasys.com/news/femasys-announces-partnership-with-refuah-health-center-to-expand-first-line-access-to-femaseed-in-community-based-care/ 2026-01-13T09:00:00+00:00 https://femasys.com/news/femasys-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement/ 2026-01-14T09:00:00+00:00 https://femasys.com/news/femasys-expands-european-commercial-footprint-with-swiss-partner-for-fembloc-femaseed-and/ 2026-02-03T09:00:00+00:00 https://femasys.com/news/femasys-receives-ama-cpt-editorial-panel-approval-for-new-category-iii-cpt-code-for-femaseed-intratubal-insemination/ 2026-02-23T09:00:00+00:00 https://femasys.com/news/femasys-announces-fembloc-permanent-birth-control-has-achieved-mdsap-certification/ 2026-02-26T09:00:00+00:00 https://femasys.com/news/femasys-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2026-02-27T09:00:00+00:00 https://femasys.com/news/femasys-advances-fembloc-toward-u-s-approval-with-initiation-of-pivotal-trial-enrollment/ 2026-03-10T09:00:00+00:00 https://femasys.com/news/femasys-shareholder-update-2025-in-review/ 2026-03-10T10:00:00+00:00 https://femasys.com/news/femasys-appoints-dr-kenneth-d-eichenbaum-to-board-of-directors/ 2026-03-18T09:00:00+00:00 https://femasys.com/news/femasys-regains-compliance-with-nasdaq-listing-requirements/ 2026-07-22T16:33:03+00:00 https://femasys.com/news/femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-corporate/ 2026-07-22T16:33:31+00:00 https://femasys.com/news/femasys-expands-fertility-care-portfolio-in-europe-with-ce-mark-approval-for-femhsg-catheter/ 2026-07-22T16:33:58+00:00 https://femasys.com/news/femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial/ 2026-07-22T16:36:56+00:00 https://femasys.com/news/femasys-launches-femaseed-complete-for-ob-gyns-at-acog-2026/ 2026-07-22T16:37:28+00:00 https://femasys.com/news/femasys-shareholder-update-q1-2026/ 2026-07-22T16:37:53+00:00 https://femasys.com/news/femasys-drives-international-growth-with-israeli-market-entry-for-fertility-portfolio/ 2026-07-22T16:38:15+00:00 https://femasys.com/news/femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-execution-and-advance-commercial-growth/ 2026-07-22T16:39:22+00:00 https://femasys.com/news/femasys-announces-financial-results-for-year-ended-december-31-2025-and-provides-corporate/ 2026-07-22T16:39:45+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Secures-30-Million-Private-Placement-with-Potential-Proceeds-of-Up-to-90-Million/default.aspx 2026-08-07T16:32:20+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Announces-FDA-Approval-of-Modular-PMA-Submission-Approach-for-FemBloc/default.aspx 2026-08-20T13:33:38+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Announces-Financial-Results-for-Quarter-Ended-June-30-2026-and-Provides-Corporate-Update/default.aspx 2026-08-20T14:43:33+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Announces-FDA-Approval-of-Modular-PMA-Submission-Approach-for-FemBloc/default.aspx 2026-08-20T14:45:14+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Partners-with-UNC-Health-to-Introduce-Its-FemaSeed-Fertility-Portfolio-Across-Statewide-OBGYN-Care-Locations/default.aspx?utm_content=385352232&utm_medium=social&utm_source=linkedin&hss_channel=lcp-1134363#new_tab 2026-09-09T15:25:59+00:00 https://ir.femasys.com/news/news-details/2026/Femasys-Advances-OBGYN-Expansion-with-Adoption-of-FemaSeed-Fertility-Portfolio-by-Minnesota-Womens-Care/default.aspx#new_tab 2026-09-15T13:48:49+00:00